美股
Lead report
ResMed Guides 62%-63% Gross Margin for FY2026, Plans $175M Q4 Buyback, Closes Noctrix Acquisition in June
ResMed issues gross margin guidance of 62%-63% for fiscal 2026, announces a $175M+ share buyback for Q4, and targets June 1 completion of its $340M acquisition of Noctrix Health to expand into neuromodulation.
